Journalartikel

Jahr der Veröffentlichung: 2023

Seiten: 134-139

Zeitschrift: The Journal of Heart and Lung Transplantation

Bandnummer: 42

Heftnummer: 1

ISSN: 1053-2498

eISSN: 1557-3117

DOI Link: https://doi.org/10.1016/j.healun.2022.08.011

Verlag: Elsevier

Abstract: 
BACKGROUND: The combination of riociguat , interventional balloon pulmonary angioplasty (BPA) is currently used to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The aim of the present study was to evaluate the impact of this combination therapy on the prognosis of inoperable CTEPH patients by comparing the long-term survival rates of patients under-going combination therapy with riociguat and BPA with those of inoperable patients from the first international CTEPH registry who did not receive specific treatment.METHODS: Between March 2014 and August 2019, 138 technically inoperable patients were included in the present prospective, observational cohort study when they were treated with riociguat and BPA at a single CTEPH referral center. Long-term survival of this cohort was compared using propensity score matching with that of inoperable patients recruited between 2007 and 2009 in the first international CTEPH registry. Kaplan-Meier methods were used to evaluate differences in outcomes.RESULTS: Whereas the survival rate in the historical group was 84.6% in the first year, 76.6% in the second, 68.5% in the third , 58.5% in the fifth year after diagnosis, implementation of riociguat/ BPA led to survival rates of 100%, 96.7%, 92.9%, and 90% in the respective follow-up periods. In a comparison of 83 well-matched pairs from the 2 cohorts, survival was markedly better in the group treated with riociguat and BPA than in the historical cohort (HR = 0.145, 95% CI 0.05, 0.421).CONCLUSION: The combination of riociguat and BPA for the treatment of inoperable CTEPH is associ-ated with excellent 5-year survival rates. J Heart Lung Transplant 2023;42:134-139 (c) 2022 International Society for Heart and Lung Transplantation. All rights reserved.

Harvard-Zitierstil: Wiedenroth, C., Rolf, A., Steinhaus, K., Adameit, M., Kriechbaum, S., Haas, M., et al. (2023) Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension, The Journal of Heart and Lung Transplantation, 42(1), pp. 134-139. https://doi.org/10.1016/j.healun.2022.08.011

APA-Zitierstil: Wiedenroth, C., Rolf, A., Steinhaus, K., Adameit, M., Kriechbaum, S., Haas, M., Roller, F., Hamm, C., Ghofrani, H., Mayer, E., Breithecker, A., Guth, S., & Liebetrau, C. (2023). Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension. The Journal of Heart and Lung Transplantation. 42(1), 134-139. https://doi.org/10.1016/j.healun.2022.08.011